The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
Study Name on ClinicalTrials.gov (link is external) | Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients |
---|---|
Study Drug | QR-010 |
Type of Study Drug | CFTR Modulation |
Study Title | Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis |
Study Phase | 1b |
Study Sponsor | ProQR Therapeutics |
https://clinicaltrials.gov/ct2/show/NCT02532764 (link is external) | |
Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
Age | 18 Years to 60 Years |